Profession-specific resources


  • Heart Failure Algorithm

Each version has the same content but different face plate

These algorithms are intended to ensure the health care professional has the tools, resources and knowledge to care for their HF patient as well as the resources to teach their patients about HF to ensure they can co-manage their HF care. Each algorithm is based on the most up to date evidence based HF literature.

HF Algorithm Standard Care HF Algorithm Still Symptomatic Hf Algorithm Step Care

Patient Assessment Form

This practice resource guides the GP to ensure they assess the most relevant HF specific criteria with each of their HF patients. This allows them to gather all the appropriate information to assess a HF patient and the assessment guides the patient’s treatment plan. The identified assessment fields are based on the lasted HF literature.

Patient Assessment Form

Patient Questionnaire

This practice resource outlines all the important information a GP needs to effectively assess their HF patients and decided on their treatment plan.  The identified data fields are based on the lasted HF literature.

Patient Questionnaire

 Provincial Process for Initating, titrating sacubitril/valsartan (ENTRESTO)

Attn: physicians and nurse practitioners 

Health Canada has recently approved a new medication for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF). Approval was based on results from the PARADIGM-HF trial, which demonstrated that sacubitril/valsartan reduced the relative risk of cardiovascular death and hospitalization by 20% for patients with chronic HF (NYHA Class II-IV) and a left ventricular ejection fraction of <40%, despite optimally tolerated guideline-driven HF therapies.

 There are very specific considerations for this medication that prescribers must be aware of, as well as significant drug interactions with current HF medications that could impact patient safety and health care utilization in BC.

 In attempts to ensure appropriate utilization of sacubitril/valsartan, and to assess its impact on health care utilization in BC outside of the clinical trial setting, Cardiac Services BC and BC’s Heart Failure Network experts have created processes for prescribers:

Formal resources are coming soon



(in development)


  • Nurse Practitioners

(in development)


(in development)

Social Work

(in development)